Autoantibodies in Pandemrix^®-induced narcolepsy: Nine candidate autoantigens fail the conformational autoantibody test

References

• Szakacs A, Darin N, Hallbook T. Increased childhood incidence of narcolepsy in western Sweden after H1N1 influenza vaccination. Neurology. 2013;80:1315–1321.
   PubMed Web of Science ®Google Scholar
• Persson I, Granath F, Askling J, et al. Risks of neurological and immune-related diseases, including narcolepsy, after vaccination with Pandemrix: a population- and registry-based cohort study with over 2 years of follow-up. J Intern Med. 2014;275:172–190.
   PubMed Web of Science ®Google Scholar
• Nohynek H, Jokinen J, Partinen M, et al. AS03 adjuvanted AH1N1 vaccine associated with an abrupt increase in the incidence of childhood narcolepsy in Finland. PLoS One. 2012;7:e33536.
   PubMed Web of Science ®Google Scholar
• Tafti M, Hor H, Dauvilliers Y, et al. DQB1 locus alone explains most of the risk and protection in narcolepsy with cataplexy in. Europe Sleep. 2014;37:19–25.
   PubMed Web of Science ®Google Scholar
• Mignot E, Lin L, Rogers W, et al. Complex HLA-DR and -DQ interactions confer risk of narcolepsy-cataplexy in three ethnic groups. Am J Hum Genet. 2001;68:686–699.
   PubMed Web of Science ®Google Scholar
• Kornum BRS, Knudsen HM, Ollila F, et al. Narcolepsy. Nat Rev Dis Primers. 2017;3:16100.
   PubMed Web of Science ®Google Scholar
• Thannickal TC, Moore RY, Nienhuis R, et al. Reduced number of hypocretin neurons in human narcolepsy. Neuron. 2000;27:469–474.
   PubMed Web of Science ®Google Scholar
• Wang C, Wang Q, Ji B, et al. The Orexin/Receptor System: molecular mechanism and therapeutic potential for neurological diseases. Front Mol Neurosci. 2018;11:220.
   PubMed Web of Science ®Google Scholar
• Luo G, Ambati A, Lin L, et al. Autoimmunity to hypocretin and molecular mimicry to flu in type 1 narcolepsy. Proc Natl Acad Sci USA. 2018;115:E12323–e12332.
   PubMed Web of Science ®Google Scholar
• Latorre D, Kallweit U, Armentani E, et al. T cells in patients with narcolepsy target self-antigens of hypocretin neurons. Nature. 2018;562:63–68.
   PubMed Web of Science ®Google Scholar
• Tanaka S, Honda Y, Inoue Y, et al. Detection of autoantibodies against hypocretin, hcrtrl, and hcrtr2 in narcolepsy: anti-Hcrt system antibody in narcolepsy. Sleep. 2006;29:633–638.
   PubMed Web of Science ®Google Scholar
• Knudsen S, Mikkelsen JD, Jennum P. Antibodies in narcolepsy-cataplexy patient serum bind to rat hypocretin neurons. Neuroreport. 2007;18:77–79.
   PubMed Web of Science ®Google Scholar
• Martinez-Rodriguez JE, Sabater L, Graus F, et al. Evaluation of hypothalamic-specific autoimmunity in patients with narcolepsy. Sleep. 2007;30:27–28.
   PubMed Web of Science ®Google Scholar
• Luo G, Lin L, Jacob L, et al. Absence of anti-hypocretin receptor 2 autoantibodies in post pandemrix narcolepsy cases. PLoS One. 2017;12:e0187305.
   PubMed Web of Science ®Google Scholar
• Giannoccaro MP, Waters P, Pizza F, et al. Antibodies against hypocretin receptor 2 are rare in narcolepsy. Sleep. 2017;40.
   PubMed Web of Science ®Google Scholar
• Ahmed SS, Volkmuth W, Duca J, et al. Antibodies to influenza nucleoprotein cross-react with human hypocretin receptor 2. Sci Transl Med. 2015;7:294ra105.
   PubMed Web of Science ®Google Scholar
• Toyoda H, Tanaka S, Miyagawa T, et al. Anti-Tribbles homolog 2 autoantibodies in Japanese patients with narcolepsy. Sleep. 2010;33:875–878.
   PubMed Web of Science ®Google Scholar
• Kawashima M, Lin L, Tanaka S, et al. Anti-Tribbles homolog 2 (TRIB2) autoantibodies in narcolepsy are associated with recent onset of cataplexy. Sleep. 2010;33:869–874.
   PubMed Web of Science ®Google Scholar
• Cvetkovic-Lopes V, Bayer L, Dorsaz S, et al. Elevated Tribbles homolog 2-specific antibody levels in narcolepsy patients. J Clin Invest. 2010;120:713–719.
   PubMed Web of Science ®Google Scholar
• Lind A, Ramelius A, Olsson T, et al. A/H1N1 antibodies and TRIB2 autoantibodies in narcolepsy patients diagnosed in conjunction with the Pandemrix vaccination campaign in Sweden 2009–2010. J Autoimmun. 2014;50:99–106.
   PubMed Web of Science ®Google Scholar
• Bergman P, Adori C, Vas S, et al. Narcolepsy patients have antibodies that stain distinct cell populations in rat brain and influence sleep patterns. Proc Natl Acad Sci USA. 2014;111:E3735–E3744.
   PubMed Web of Science ®Google Scholar
• Sadam H, Pihlak A, Kivil A, et al. Prostaglandin D2 receptor DP1 antibodies predict vaccine-induced and spontaneous narcolepsy type 1: large-scale study of antibody profiling. EBioMedicine. 2018;29:47–59.
   PubMed Web of Science ®Google Scholar
• Häggmark-Månberg A, Zandian A, Forsström B, et al. Autoantibody targets in vaccine-associated narcolepsy. Autoimmunity. 2016;49:421–433.
   PubMed Web of Science ®Google Scholar
• Swaab DF. Neuropeptides in hypothalamic neuronal disorders. Int Rev Cytol. 2004;240:305–375.
   PubMedGoogle Scholar
• Nixon JP, Mavanji V, Butterick TA, et al. Sleep disorders, obesity, and aging: the role of orexin. Ageing Res Rev. 2015;20:63–73.
   PubMed Web of Science ®Google Scholar
• Juvodden HT, Alnaes D, Lund MJ, et al. Widespread white matter changes in post-H1N1 narcolepsy type 1 patients and 1st degree relatives. Sleep. 2018;41.
   PubMed Web of Science ®Google Scholar
• Park YK, Kwon OH, Joo EY, et al. White matter alterations in narcolepsy patients with cataplexy: tract-based spatial statistics. J Sleep Res. 2016;25:181–189.
   PubMed Web of Science ®Google Scholar
• Srivastava R, Aslam M, Kalluri SR, et al. Potassium channel KIR4.1 as an immune target in multiple sclerosis. N Engl J Med. 2012;367:115–123.
   PubMed Web of Science ®Google Scholar
• Zhong R, Liang J, Tao A, et al. Anti-KIR4.1 antibodies in Chinese patients with central nervous system inflammatory demyelinating disorders. Neuroimmunomodulation. 2016;23:295–300.
   PubMed Web of Science ®Google Scholar
• Navas-Madronal M, Valero-Mut A, Martinez-Zapata MJ, et al. Absence of antibodies against KIR4.1 in multiple sclerosis: a three-technique approach and systematic review. PLoS One. 2017;12:e0175538.
   PubMed Web of Science ®Google Scholar
• Higuchi O, Nakane S, Sakai W, et al. Lack of KIR4.1 autoantibodies in Japanese patients with MS and NMO. Neurol Neuroimmunol Neuroinflamm. 2016;3:e263.
   PubMed Web of Science ®Google Scholar
• Brill L, Goldberg L, Karni A, et al. Increased anti-KIR4.1 antibodies in multiple sclerosis: could it be a marker of disease relapse? Mult Scler. 2015;21:572–579.
   PubMed Web of Science ®Google Scholar
• Marino M, Frisullo G, Di Sante G, et al. Low reliability of anti-KIR4.183-120 peptide auto-antibodies in multiple sclerosis patients. Mult Scler. 2018;24:910–918.
   PubMedGoogle Scholar
• Marnetto F, Valentino P, Caldano M, et al. Detection of potassium channel KIR4.1 antibodies in multiple sclerosis patients. J Immunol Methods. 2017;445:53–58.
   PubMed Web of Science ®Google Scholar
• Nerrant E, Salsac C, Charif M, et al. Lack of confirmation of anti-inward rectifying potassium channel 4.1 antibodies as reliable markers of multiple sclerosis. Mult Scler. 2014;20:1699–1703.
   PubMed Web of Science ®Google Scholar
• Schirmer L, Srivastava R, Kalluri SR, et al. Differential loss of KIR4.1 immunoreactivity in multiple sclerosis lesions. Ann Neurol. 2014;75:810–828.
   PubMed Web of Science ®Google Scholar
• Ayoglu B, Mitsios N, Kockum I, et al. Anoctamin 2 identified as an autoimmune target in multiple sclerosis. Proc Natl Acad Sci USA. 2016;113:2188–2193.
   PubMed Web of Science ®Google Scholar
• Zlegler B, Strebelow M, Rjasanowski I, et al. A monoclonal antibody-based characterization of autoantibodies against glutamic acid decarboxylase in adults with latent autoimmune diabetes. Autoimmunity. 1998;28:61–68.
   PubMed Web of Science ®Google Scholar
• Jastrzebska-Bohaterewicz E, Gardas A. Proportion of antibodies to the A and B immunodominant regions of thyroid peroxidase in Graves and Hashimoto disease. Autoimmunity. 2004;37:211–216.
   PubMed Web of Science ®Google Scholar
• Grennan Jones F, Ziemnicka K, Sanders J, et al. Analysis of autoantibody epitopes on human thyroid peroxidase. Autoimmunity. 1999;30:157–169.
   PubMed Web of Science ®Google Scholar
• Liu E, Eisenbarth GS. Accepting clocks that tell time poorly: fluid-phase versus standard ELISA autoantibody assays. Clin Immunol. 2007;125:120–126.
   PubMed Web of Science ®Google Scholar
• Winqvist O, Karlsson FA, Kampe O. 21-Hydroxylase, a major autoantigen in idiopathic Addison's disease. Lancet. 1992;339:1559–1562.
   PubMed Web of Science ®Google Scholar
• Pihoker C, Gilliam LK, Hampe CS, et al. Autoantibodies in diabetes. Diabetes. 2005;54(Suppl 2):S52–S61.
   PubMed Web of Science ®Google Scholar
• Johansson J, Becker C, Persson NG, et al. C-peptide in dried blood spots. Scand J Clin Lab Invest. 2010;70:404–409.
   PubMed Web of Science ®Google Scholar
• Grubin CE, Daniels T, Toivola B, et al. A novel radioligand binding assay to determine diagnostic accuracy of isoform-specific glutamic acid decarboxylase antibodies in childhood IDDM. Diabetologia. 1994;37:344–350.
   PubMed Web of Science ®Google Scholar
• Jonsdottir B, Larsson C, Lundgren M, et al. Childhood thyroid autoimmunity and relation to islet autoantibodies in children at risk for type 1 diabetes in the diabetes prediction in skåne (DiPiS) study. Autoimmunity. 2018;51:228–237.
   PubMed Web of Science ®Google Scholar
• Doyle HA, Yang M-L, Raycroft MT, et al. Autoantigens: novel forms and presentation to the immune system. Autoimmunity. 2014;47:220–233.
   PubMed Web of Science ®Google Scholar
• Mannoor K, Xu Y, Chen C. Natural autoantibodies and associated B cells in immunity and autoimmunity. Autoimmunity. 2013;46:138–147.
   PubMed Web of Science ®Google Scholar